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MicroRNAs (miRNAs) can notably control many targets each and regulate entire cellular
pathways, but whether miRNAs can regulate complete neurotransmission processes is
largely unknown. Here, we report that miRNAs with complementary sequence motifs
to the key genes involved in acetylcholine (ACh) synthesis and/or packaging show
massive overlap with those regulating ACh degradation. To address this topic, we
first searched for miRNAs that could target the 3′-untranslated regions of the choline
acetyltransferase (ChAT) gene that controls ACh synthesis; the vesicular ACh transporter
(VAChT), encoded from an intron in the ChAT gene and the ACh hydrolyzing genes
acetyl- and/or butyrylcholinesterase (AChE, BChE). Intriguingly, we found that many
of the miRNAs targeting these genes are primate-specific, and that changes in their
levels associate with inflammation, anxiety, brain damage, cardiac, neurodegenerative,
or pain-related syndromes. To validate the in vivo relevance of this dual interaction, we
selected the evolutionarily conserved miR-186, which targets both the stress-inducible
soluble “readthrough” variant AChE-R and the major peripheral cholinesterase BChE. We
exposed mice to predator scent stress and searched for potential associations between
consequent changes in their miR-186, AChE-R, and BChE levels. Both intestinal miR-186 as
well as BChE and AChE-R activities were conspicuously elevated 1 week post-exposure,
highlighting the previously unknown involvement of miR-186 and BChE in psychological
stress responses. Overlapping miRNA regulation emerges from our findings as a recently
evolved surveillance mechanism over cholinergic neurotransmission in health and disease;
and the corresponding miRNA details and disease relevance may serve as a useful
resource for studying the molecular mechanisms underlying this surveillance.
Keywords: acetlycholinesterase, butyrylcholinesterase, choline acetyltransferase, vesicular acetylcholine
transporter, microRNA-186, cholinergic signaling, primate-specific microRNAs
INTRODUCTION
MicroRNAs (miRNAs) are small, 20–25 nucleotides long, non-
coding RNAmolecules, each of which can predictably targetmany
protein-coding messenger RNA (mRNA) transcripts to silence
them post-transcriptionally. Mammalian miRNAs bind target
mRNAs via a short “seed” sequence, such that many miRNAs can
target the same mRNAs, and different mRNAs may be targeted
by a single miRNA gene (Bartel, 2009). Interestingly, miRNAs
often target different mRNAs all involved in a particular bio-
logical function (Chen et al., 2004). This has been extensively
studied in various cancers (Kefas et al., 2008; Papagiannakopoulos
et al., 2008; Levy et al., 2010; Lupini et al., 2013), but the con-
trol by miRNAs of specific neurotransmission processes remained
largely unexplored. In principle, one would predict that the
synthesis, packaging in neuronal vesicles and destruction or re-
uptake of a certain neurotransmitter should be co-regulated;
this, in turn implies that some miRNAs may co-suppress two or
more of the mRNA transcripts involved in regulating the lev-
els of certain neurotransmitters, and that modified expression
of such miRNAs might be involved in diseases associated with
impaired regulation of this neurotransmission pathway. Based on
this working hypothesis, we studied miRNA-mediated regulation
of mRNA transcripts involved in the synthesis, vesicle packaging,
and destruction of acetylcholine (ACh).
MiRNA-binding sequence motifs are primarily located at
the 3′-untranslated region (3′-UTR) of the mRNA transcript
(Bartel, 2009). Therefore, we interrogated the 3′-UTR domains
in the choline acetyltransferase (ChAT) gene, which is respon-
sible for ACh synthesis and the vesicular acetylcholine trans-
porter (VAChT), encoded from the first intron in the ChAT gene
(Erickson et al., 1994; Eiden, 1998). The VAChT transcript has its
own 3′-UTR, which might suggest that it can be regulated by dis-
tinct miRNAs. Given that released ACh is degraded by the ACh
hydrolyzing enzymes acetyl- and butyrylcholinesterase (AChE,
BChE) (Meshorer and Soreq, 2006), and since increased AChE
synthesis may be linked with decreased ChAT production (Kaufer
et al., 1998), we further searched for potential overlaps in the pre-
dicted miRNAs between the human ChAT/VAChT 3′-UTRs and
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the alternative 3′-UTR choices of the major variants of AChE
mRNA, the “synaptic” AChE-S and the “read-through” variant
AChE-R which shares its 3′-UTR with the “erythrocytic” AChE-
E isoform and is known to be induced under stress (Meshorer
and Soreq, 2006). Of note, the AChE-S variant possesses a consid-
erably shorter 3′-UTR compared to AChE-R (Hanin and Soreq,
2011) with further likelihood of differential miRNA regulation
for the AChE-R and AChE-S targets. The BChE gene, completing
the series of regions to be analyzed, has a different 3′-UTR with
lower G, C-content (Soreq and Seidman, 2001), demonstrating
sequence differences. All of these regions are functionally involved
in cholinergic signaling, and we therefore designated the corre-
sponding miRNAs “CholinomiRs.” A schematic overview of the
transcripts involved in this pathway is given in Figure 1.
There were only a few overlaps between the predicted
CholinomiRs regulating the synthesis and destruction of ACh.
In contrast, we identified numerous overlaps between those
CholinomiRs controlling ACh packaging and its synthesis;
suggesting that miRNAs play an important role in selectively
co-regulating cholinergic signaling by adapting the rates and
efficacy of ACh packaging and destruction. Changes in these
CholinomiRs, of which many are primate-specific, were further
reported by others in inflammation and anxiety, brain damage,
pain, cardiac, and neurodegenerative diseases, all of which are
known for cholinergic signaling impairments.
To test the relevance of our predictions for in vivo conditions,
we subjected mice to the long-lasting predator scent stress
(Zimmerman et al., 2012) and tested, 1 week later, for changes
in one miRNA, miR-186 and its predicted targets AChE-R and
BChE. Given our previous findings of miRNA regulation of
cholinergic-mediated production of intestinal miR-132 (Shaked
et al., 2009), we quantified miR-186 levels in intestinal sec-
tions and measured cholinesterase activities. We found that
predator scent stress induces intestinal increases in both the
cholinesterases-targeting miR-186 and in the activities of the
targeted cholinesterases. Our findings support the hypothesis
FIGURE 1 | Schematic overview of ACh synthesis, packaging, and
destruction. (A) The choline acetyl transferase (ChAT) gene responsible
for ACh synthesis is 56 kb in size and all its splice variants have the
same 3′UTR. (B) The vesicular acetylcholine transporter (VAChT)
controlling ACh packaging into vesicles is encoded from the first intron of
the ChAT gene. The VAChT gene is only 2 kb in length, yet it has its
own 3′UTR. Once released, ACh should be degraded into Acetate and
Choline by one of the splice variants of AChE or BChE, depending on its
site of release. (C,D) The AChE gene is 6 kb in size, and its mRNA
transcript is spliced to yield the major AChE-S and AChE-R splice variants
with distinct 3′-UTR domains. (E) The BChE gene is 65 kb in size and
yields only one known splice variant.
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that overlapping CholinomiR regulation serves as a recently
evolved surveillance mechanism that can balance cholinergic
signaling in brain and peripheral systems. The detailed lists of
these miRNAs and their potential involvements with different
diseases may be a valuable resource for researchers interested in
both basic and translational aspects of key neuroinflammation
and pain-related disorders.
MATERIALS AND METHODS
BIOINFORMATICS APPROACHES
3′-UTR sequences of the human ChAT, VAChT, AChE-S, AChE-
R, and BChE transcripts were acquired from the NCBI nucleotide
database (Entrez Nucleotide, 2010 http://www.ncbi.nlm.nih.gov/
nuccore/). These sequences are 380, 58, 219, 963, and 477
nucleotides long, respectively. MiRNA-mRNA interactions were
addressed by using four different algorithms, miRBase (Last
update in June 2013, http://www.mirbase.org/), TargetScan (Last
update in June 2012, http://www.targetscan.org/vert_50/), micro-
cosm (version 5) (http://www.ebi.ac.uk/enright-srv/microcosm/
htdocs/targets/v5/) and miRanda (Last update in August 2010,
http://www.microrna.org/microrna/home.do) which were last
updated in June 2013, June 2012 and August 2010, respectively.
All predictions ensured a threshold P-value < 0.05, and analysis
specifications allowed both evolutionarily conserved and non-
conserved miRNAs, which further enabled us to differentiate
between primate-specific and evolutionarily conserved miRNAs.
To gainmore information on the identifiedmiRNAs and assess
their prospects to interact with their targets, we determined the G,
C content of all identified miRNAs using G, C content calculator
algorithms (http://www.endmemo.com/bio/gc.php). We further
focused on the overlapping miRNAs targeting more than one
3′-UTR of the 5 studied transcripts and distinguished primate-
specific from evolutionarily conserved miRNAs that appeared in
our list using the HomoloGen conservation score 1 that reports
genomic conservation values between tested genes from different
species. For data-mining regarding the relation to specific diseases
we utilized PubMed and Google Scholar.
EXPERIMENTAL in vivo TESTS
To experimentally test the putative association between changes
in the identified miRNAs and their protein targets under stressful
conditions, we exposed C57/B6J mice to predator scent and addi-
tionally injected them for four consecutive days with 50μg kg−1
saline, essentially as in (Zimmerman et al., 2012). 7 days later, we
removed intestinal sections from these mice and matched male
control mice, as in (Shaked et al., 2009). The mice were housed
four per cage, at 21 ± 1◦C, in a 12-h light/dark cycle. The RNA
extraction procedure followed that of (Maharshak et al., 2013)
for human intestinal biopsies. Extracted RNA from the intestinal
sections was used to quantify miR-186 and RNU6 levels by qRT-
PCR (PerfeCTa® microRNA Assay). RNU6 snRNA levels were
used to normalize the levels of miR-186. The following primers
were employed: RNU6 (Quanta, Cat. # HS-RNU6), miR-186-
5p (Quanta, Cat. # HSMIR-0186-5p), PerfeCTa® Universal PCR
1http://www.ncbi.nlm.nih.gov/
Primer (Quanta, Cat. # 95109-500). Protein extraction from the
intestinal sections was performed by using Solution D (0.01M
TRIS, 1M NaCl, 1mM EGTA, 1% T-X100). Cholinesterase activ-
ities in the tissue homogenates were determined by quantifying
acetylthiocholine hydrolysis rates (Ellman et al., 1961) in the pres-
ence or absence of iso-OMPA to selectively block BChE activities,
all as under (Arbel et al., 2014). Animal procedures followed the
ethics instructions at The Hebrew University of Jerusalem (Ethics
number of research: NS-10205-4).
STATISTICAL ANALYSIS
Collected data was summarized and displayed as mean ± stan-
dard deviation (Erickson et al., 1994) using SPSS software (ver-
sion 19.0, SPSS INC, Chicago, IL, USA). Normally distributed
variables were compared using Student’s t test. The level of
significance used for all of the above analyses was 2-tailed
p < 0.05.
RESULTS
3′-UTR sequences of the human ChAT, VAChT, AChE-S,
AChE-R, and BChE transcripts were acquired from the NCBI
nucleotide database. These sequences span 380, 58, 219, 963, and
477 nucleotides, respectively and differ in their G, C content.
We identified 42, 67, 55, 125, and 205 complementary miR-
NAs predicted to bind to the interrogated 3′-UTRs, respectively
(Table 1, for details see Supplementary Table 1). Thus, the den-
sity of miRNA binding sites in these transcripts did not simply
reflect their length, and the AChE-R and BChE mRNA tran-
scripts encoding for soluble, secreted proteins emerged as partic-
ularly susceptible for miRNA targeting. Interestingly, we found
no overlap between the VAChT and ChAT targeting miRNAs,
suggesting differential regulation of the ACh synthesis and pack-
aging processes in spite of these transcripts being subject to joint
transcriptional control. In contradistinction, 26% of the ChAT
targeting miRNAs are also predicted to target cholinesterases,
and ACh packaging and degradation seemed to share yet more
miRNAs: of 67VAChT-targeting miRNAs, 55% predictably rec-
ognize binding sites in cholinesterases as well, and 5 of them
co-target both the alternatively spliced “synaptic” AChE-S and
the stress and inflammation-inducible “read-through” AChE-R
transcript, enabling more profound suppression of ACh hydrol-
ysis (for details see Supplementary Table 2). Notable examples
involve the conserved neurodevelopment-associated hsa-miR-
125b (Martino et al., 2009) and the primate-specific hsa-miR-608
and -765 (primate specificity determined by HomoloGen conser-
vation score1).
Our working hypothesis predicted that miRNAs targeting
more than one of the five 3′-UTR domains would be more
likely than others to be causally involved in regulating this entire
pathway. Also, many believe that recent evolutionary processes re-
shaped the miRNA landscape in primates, contributing to human
higher brain functions (Khaitovich et al., 2006). To find out if
this re-shaping process affected the regulation of the choliner-
gic system, we searched for primate specificity within the group
of 76 identified miRNAs that target more than one choliner-
gic transcript (Supplementary Table 3). About half (49%) of the
VAChT and cholinesterases co-targeting miRNAs were found to
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Table 1 | Overlapping miRs are largely primate-specific.
Targeted transcripts Length of G, C-content No of predicted G, C-content of targeting % of primate specific
3′UTR [nt] of 3′UTR miRNAs miRNAs [%] miRNAs
ChAT 58 59 42 57
VAChT 380 62 67 58
AChE-S 219 66 55 59
AChE-R 963 62 125 55
BChE 477 28 205 45
VAChT + AChE-S 10 58 40
VAChT + AChE-R 24 61 54
VAChT + BChE 3 41 33
VAChT + ChAT 0 0 0
AChE-S + AChE-R 23 61 37
AChE-S + BChE 1 59 0
AChE-S + ChAT 1 82 0
AChE-R + BChE 16 46 44
AChE-R + ChAT 4 62 25
BChE + ChAT 6 52 66
AChE-S + AChE-R + VAChT 6 50
AChE-S + AChE-R + ChAT 1 100
AChE-S + BChE + VAChT 1 0
Shown are the 3 ′-UTR lengths, G, C-content and the numbers of miRNAs predicted to target each of the ChAT, VAChT, AChE-S, AChE-R, and BChE transcripts alone
and those predictably targeting more than one of these transcripts and the fractions of these miRNAs that are primate-specific.
be primate-specific (Supplementary Table 3), suggesting recently
evolved miRNA-mediated mechanisms for co-regulation of ACh
packaging and degradation (Table 1).
Of the cholinesterase targeting miRNAs, we found 16 that
predictably target both BChE and AChE-R, whereas 23 miR-
NAs show “seed” complementarity to both AChE-R and AChE-S.
However, BChE, and the synaptic AChE-S variant share only
one single miRNA (Table 1), hsa-miR-491-5p (further details on
shared miRNAs can be found in Supplementary Table 2). BChE
has a much lower G, C content than the other four transcripts
(Soreq et al., 1990); therefore, we wanted to find out whether this
is reflected in its putatively targeting miRNAs. Not surprisingly,
we found the average G, C content of BChE-targeting miRNAs
to be 45%, approximately 12% lower than the average G, C con-
tent of the miRNAs targeting the other four transcripts (Table 1,
Supplementary Table 4).
Next, we searched for the relevance of miRNAs targeting more
than one transcript involved in ACh metabolism to known dis-
ease phenotypes (Supplementary Table 5). Compatible with the
cancer-associated bias in the miRNA field, we found numer-
ous studies on cancer-related miRNAs that target more than
one transcript involved in ACh metabolism (Supplementary
Table 5), and yet more are likely to accumulate in the near future.
However, after excluding all of these cancer-related publications,
we revealed 28 out of the identified 76 miRNAs that associate
with other diseases. These could be classified into five groups:
inflammation and anxiety, brain damage, cardiac or neurode-
generative diseases and pain-related syndromes (Supplementary
Table 6). Table 2 lists these 28 miRNAs including the transcripts
they are targeting as well as their reported disease associa-
tions. Interestingly, 67% of these miRNAs play key roles in
inflammation-associated diseases and 61% of them target more
than one disease group.
Figure 2 presents the miRNAs co-targeting AChE-S and
AChE-R, BChE, and AChE-R or VAChT and AChE-R in a pie
chart classifying the shared targets and relevant diseases and high-
lighting the observed interactions between these miRNAs and
the disease phenotypes, as well as the primate specificity of part
of these miRNAs. Disease group association is shown as sur-
rounding lines of differential thicknesses, reflecting the number
of miRNAs in each group. A notable example is the evolution-
arily conserved neural-expressed miR-125b, which targets both
VAChT and AChE-R (Table 2) and associates with all five groups:
inflammation and anxiety (Manca et al., 2011; Xu et al., 2011;
Danielsson et al., 2012; Matsukawa et al., 2013), brain damage
(Rink and Khanna, 2011), neurodegenerative diseases (Lukiw and
Alexandrov, 2012) and cardiac diseases (Voellenkle et al., 2010)
and diverse pain syndromes (Imai et al., 2011; Kynast et al., 2013;
Monastyrskaya et al., 2013; Sakai et al., 2013). Known associa-
tion of each of these diseases with impaired cholinergic signaling
(Shenhar-Tsarfaty et al., 2013a,b) supports the notion of physio-
logical significance for surveillance by the overlapping miRNAs.
A primate-specific example involves miR-765, which co-targets
AChE-R and VAChT. Redell (Redell et al., 2010) found that miR-
765 is upregulated in the plasma of patients after traumatic brain
injury, compatible with changes in serum cholinesterases in post-
stroke patients (Ben Assayag et al., 2010). Additionally, miR-765
targets the neurotrophin-3 receptor 3′UTR, and Muiños-Gimeno
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Table 2 | Disease association of predicted CholinomiRs.
Target miRNA Inflammation and
anxiety
Brain damage Cardiac diseases Neurodegenerative
diseases
Pain
R, V hsa-miR-125a-5p Murata et al., 2013 Rink and Khanna,
2011
hsa-miR-125b Manca et al., 2011; Rink
and Khanna, 2011; Xu
et al., 2011; Danielsson
et al., 2012; Lukiw and
Alexandrov, 2012;
Matsukawa et al., 2013
Rink and Khanna,
2011
Voellenkle et al., 2010 Lukiw and
Alexandrov, 2012
hsa-miR-298 Liu et al., 2010
hsa-miR-663 Xu et al., 2011
hsa-miR-675 Lu et al., 2012
hsa-miR-7 Shaoqing et al., 2011;
Etoh et al., 2013;
Oshikawa et al., 2013
Archacki et al., 2003 Junn et al., 2009;
Wong et al., 2013a,b
Sakai et al., 2013
hsa-miR-765 Muinos-Gimeno et al.,
2009
Redell et al., 2010
R, B hsa-miR-129-5p Wang et al., 2011
hsa-miR-186 Lerman et al., 2011 Bostjancic et al., 2009
hsa-miR-199a-5p Paraskevi et al., 2012 Abdellatif, 2011 Monastyrskaya et al.,
2013
hsa-miR-200b Chen et al., 2012 Lee et al., 2010 Imai et al., 2011
hsa-miR-200c Paraskevi et al., 2012 Lee et al., 2010
hsa-miR-429 Lee et al., 2010 Imai et al., 2011
hsa-miR-590-3p Villa et al., 2011
S, R hsa-miR-7f-2* Xie et al., 2011 Tan et al., 2009 Schipper et al., 2007
hsa-miR-7g Takagi et al., 2010
hsa-miR-24 Iliopoulos et al., 2009 Zhu and Fan, 2012 Wang et al., 2012c;
Zhang et al., 2013
hsa-miR-124-3p Doeppner et al., 2013;
Dutta et al., 2013;
Matsumoto et al.,
2013; Sun et al., 2013
Kynast et al., 2013
hsa-miR-132 Shaked et al., 2009;
Murata et al., 2010;
Hanieh and Alzahrani,
2013; Maharshak et al.,
2013; Shaltiel et al.,
2013
Lusardi et al., 2010;
Chen-Plotkin et al.,
2012; Valiyaveettil
et al., 2013
Katare et al., 2011; Jin
et al., 2012; Eskildsen
et al., 2013
Lau et al., 2013;
Lungu et al., 2013;
Wong et al., 2013a
hsa-miR-194 Matsumoto et al.,
2013
hsa-miR-198 Hoekstra et al., 2010
(Continued)
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Table 2 | Continued
Target miRNA Inflammation and
anxiety
Brain damage Cardiac diseases Neurodegenerative
diseases
Pain
hsa-miR-423 Lerman et al., 2011 Keller et al., 2011;
Goren et al., 2012;
Dickinson et al., 2013;
Oliveira-Carvalho
et al., 2013
Bhattacharyya and
Bandyopadhyay, 2013
hsa-miR-4329 Gupta et al., 2013
R, C hsa-miR-149 Diaz-Prado et al., 2012 Van Rooij et al., 2008
S, V hsa-miR-149* Santini et al., 2013
B, C hsa-miR-193b* Wang et al., 2012a,b
S, B, V hsa-miR-491-5p Iborra et al., 2013 Yuan et al., 2013 Wang et al., 2011
S, R, V hsa-miR-920 Meder et al., 2011
Shown are miRNAs sorted by their putative targets and the relevant reports on their disease group association. Primate specific miRNAs are marked in orange. The
abbreviations C, V, S, R, and B stand for ChAT, VAChT, AChE-S, AChE-R, and BChE, respectively.
(Muinos-Gimeno et al., 2009) discovered a single nucleotide
change located in the miR-765 binding site of this receptor’s
mRNA 3′UTR to be associated with panic disorder. Neurotrophin
receptors regulate cholinergic signaling (Naumann et al., 2002),
which associates with stress reactions (Kaufer et al., 1998; Sklan
et al., 2004) as well as with RNA metabolism changes in the
Alzheimer’s brain (Berson et al., 2012; Lau et al., 2013); predict-
ing that disrupted association of miRNAs with these receptors
would impair cholinergic signaling and could increase the risk of
anxiety-related diseases.
To experimentally test for in vivo association of stress-
induced changes in the identified miRNAs and their putative
target genes, we selected the evolutionarily conserved miR-186
which predictably targets the two soluble cholinesterases, BChE
and AChE-R. Of those, AChE-R increases under psychological
stress were well documented (Kaufer et al., 1998; Cohen et al.,
2002; Meshorer et al., 2005; Shaltiel et al., 2013), including the
serum (Sklan et al., 2004), but BChE’s involvement was never
approached. In our current study, we quantified miR-186 lev-
els in intestinal biopsies prepared from male C57BJ mice 7 days
following 10min exposure to cat litter (predator scent stress)
and injection for four consecutive days with 50μg kg−1 saline
(Zimmerman et al., 2012) compared to matched controls (n = 5
mice per group). In the intestinal biopsies, miR-186 expression
normalized to the house-keeping short RNA RNU6 showed a 1.6-
fold increase (p < 0.016) in pre-stressed mice. In parallel, these
mice showed a 1.8-fold elevation in total cholinesterase activities
(p < 0.003, Student’s t test) as well as a less pronounced 1.6-fold
increase in AChE levels (p < 0.054). Figure 3 presents these find-
ings, demonstrating directly associated changes in the intestinal
levels of the miR-186 and its two cholinergic regulating targets.
DISCUSSION
Combined use of four different bioinformatics algorithms identi-
fied a large number of miRNAs putatively targeting the 3′UTRs
of ChAT, VAChT, AChE-S, AChE-R, and BChE. MiRNAs can
notably regulate whole biological pathways; for example, miR-
181 controls mouse hematopoiesis (Chen et al., 2004), miR-608
targets two inflammation-related transcripts, CDC42 and IL6
(Jeyapalan et al., 2011; Kang et al., 2011) and miR-221 controls
multiple cancer pathways (Lupini et al., 2013). To challenge the
possibility that certainmiRNAs likewise regulate AChmetabolism
and belong to the family of CholinomiRs, we searched for miR-
NAs targeting more than one of the five transcripts involved
in the process of ACh synthesis, packaging and degradation.
Intriguingly, packaging more than synthesis of ACh emerged as
being co-regulated with its degradation, suggesting a dynamically
controlled surveillance of these two processes. Furthermore, these
findings highlight the option of differential post-transcriptional
regulation of VAChT and ChAT, which share the same promoter
but have distinct 3′-UTR domains.
The numbers of miRNAs we identified are likely to be under-
estimated due to the exclusion of all the cancer-related miRNAs,
which may be linked to cholinergic signaling as well. However,
it is noteworthy that many of the miRNAs associated with ACh
metabolism are primate-specific. This implies that there are no
mouse models to study their function and influence, decreasing
the likelihood of experimental animal studies of these miRNAs.
Nevertheless, we found many human disease-association studies
that demonstrate putative links of these miRNAs to inflam-
mation and possibly reflecting the inflammatory blockade by
ACh (Tracey, 2010). In comparison, only a few of the identi-
fied miRNAs appear to be largely modified in neurodegenerative
diseases such as Alzheimer’s disease, perhaps because cholin-
ergic neurons decline early in the Alzheimer’s brains (Mcgeer
et al., 1984), so that it may be too late to find miRNAs play-
ing a role in ACh metabolism in late stage brain samples from
Alzheimer’s patients. An exception is the AChE-targeted miR-
132, which shows a drastic decline in the Alzheimer’s brain
(Lau et al., 2013).
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FIGURE 2 | MiRNAs targeting AChE-S and AChE-R, BChE and AChE-R or
VAChT and AChE-R show associations to different disease groups
related to cholinergic signaling. The pie chart classifies the shared targets,
as well as the relevant diseases and highlights the observed interactions
between them. Disease group association is shown as surrounding lines of
differential thicknesses, reflecting the number of miRNAs in each group. The
red, blue, green, orange and purple colored lines symbolize disease
associations with the groups of “inflammation and anxiety,” “brain damage
(e.g., stroke),” “cardiac diseases,” “neurodegenerative diseases,” and “pain,”
respectively. Note that miR-132 and miR-125b associate with all disease
groups. The monkey heads next to specific miRNA numbers symbolize
primate specificity.
The apparent relevance of CholinomiRs to diverse pain syn-
dromes is particularly intriguing (Kress et al., 2013). Thus
miR-199a-5p is expressed in the bladder’s smooth muscle and
urothelium and may play a role in bladder pain syndrome
(Monastyrskaya et al., 2013) by suppressing LIN7C, ARHGAP12,
PALS1, RND1 and PVRL1. In addition, miR-199a-5p is pre-
dicted to target both BChE and AChE-R, suggesting that its
increase would up-regulate cholinergic stimulation in the bladder,
which could also contribute to pain reactions. Likewise, miR-200b
and miR-429 predictably target BChE and AChE-R, and changes
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FIGURE 3 | Intestinal miR-186 increases under predator scent stress
are accompanied by elevated BChE and AChE activities. Top: The
nucleotide sequence of the BChE and AChE-R-targeting miR-186 and
schemes of its AChE-R and BChE mRNA targets. The “seed” sequence is
underlined. (A) qRT-PCR quantification normalized to RNU6 levels
demonstrates reproducible RFU values and 1.6-fold excess of miR-186 in
intestinal sections from stressed mice, 7 days post-predator scent
exposure (p = 0.016). (B,C) Highly significant intestinal elevation of total
acetylthiocholine hydrolytic activity (p = 0.0032) accompanied by less
pronounced AChE activity measured in the presence of 10μM iso-OMPA
(p = 0.05). N = 5 mice per group, in all tests.
in their levels were reported under neuropathic pain following
sciatic nerve ligation within the limbic forebrain’s nucleus accum-
bens (Imai et al., 2011). This has been attributed to miR-200b/429
targeting of DNAmethyltransferase 3a (DNMT3a), which indeed
accumulated in post-synaptic neurons in the nucleus accumbens
under a neuropathic pain-like state. Such an increase may lead to
long-term silencing of several genes at the transcriptional level,
and enhanced cholinergic stimulation might contribute to this
effect. An inverse effect has intriguingly been observed for miR-
7a, which predictably targets VAChT and AChE-R and may hence
reduce the packaging efficiency of ACh and limit cholinergic
signals: miR-7a alleviates the maintenance of neuropathic pain
through regulating neuronal excitability by targeting the β2 sub-
unit of the voltage-dependent sodium channel (Sakai et al., 2013).
In all of these cases, the cholinergic targets may thus modulate the
observed pain-related effects.
Our experimental test of miR-186 relevance for stress-related
conditions revealed a direct dual association between elevated
miR-186 and parallel increases in BChE levels in intestinal tis-
sues from predator scent-injection-stressed mice. These effects
were long-lasting and were only significant for BChE, highlight-
ing for the first time, the changes in this protein as associated
with psychological stress. That both miR-186 and its BChE tar-
get show intestinal increases under stress may indicate that these
miRNA changes reflect a feedback response limiting excessive
ACh stimulation; supporting this notion, serum BChE increases
in post-stroke patients were associated with better prospects of
recovery (Shenhar-Tsarfaty et al., 2013a). Further studies will be
required to explore the molecular mechanisms underlying this
involvement.
Several limitations need to be taken into account regarding
this study. First, the search algorithms for miRNA candidates
appear to differ substantially, each yielding different results. In
our current study, we studied those miRNAs found in each of
these algorithms, to improve the prospects of identifying as many
relevant miRNAs as possible. Second, as our study spanned all
of the miRNAs that predictably target the 3′-UTRs in all of the
transcripts of interest, further studies will be required to func-
tionally validate these miRNAs not only as single targeting but
also as dually targeting more than one of these ACh metabolism-
related transcripts. Third, we utilized a data-mining approach as
before (Hanin and Soreq, 2011), and relied on explorative stud-
ies which link the identified miRNAs to disease association, but it
remains unclear if such associations reflect the disease outcome or
inversely, an effort of the system to protect itself from the disease.
Taken together, our current study highlights the importance
of interrogating the extent and dynamics of miRNA regulation at
a pathway level as a novel approach for studying the molecular
mechanisms underlying specific processes in health and disease.
Moreover, the large fraction of primate-specific miRNAs that
were identified in our study calls for paying special attention
to such cases. Given that miRNAs are considered “druggable”
molecules, for example by antisense oligonucleotide manipula-
tions (Shaked et al., 2009; Shaltiel et al., 2013), it is imperative
to search for high throughput datasets from human tissue stud-
ies of relevant diseases and perhaps engineer new mouse models
with knocked-in primate-specific miRNAs, such as miR-608. This
can become a novel approach for identifying targets for therapeu-
tic intervention with diseases where primate-specific miRNAs are
subjected to major changes. In either case, our current approach
represents the peak of an iceberg; however, it provides an initial
proof of principle for the concept of joint regulation over differ-
ent transcripts involved in specific neurotransmission pathways.
This study should further be regarded as a first step in a long
pathway, since we only focused on five transcripts out of many
involved in only one pathway, the cholinergic signaling pathway;
but there are many more transcripts, such as neurotrophin or
nicotinic and muscarinic ACh receptors playing a role in cholin-
ergic signaling. Our findings thus indicate overlapping miRNA
regulation as a new surveillance mechanism that can balance
cholinergic neurotransmission and may be of value for both
Frontiers in Molecular Neuroscience www.frontiersin.org February 2014 | Volume 7 | Article 9 | 8
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basic and translational aspects of neuroinflammation-related
disorders.
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